Novare Pharmaceuticals Announces the Issuance of a U.S. patent for its RHAMM-Binding Peptides
July 30 2015 - 2:00AM
Business Wire
- The patent covers the composition of
RHAMM-Binding peptides as well as the use of peptides for
diagnosing, and determining the prognosis for, cancer patients. The
issuance of this patent is a significant milestone for Novare,
which has an exclusive license to the patented technology.
Novare Pharmaceuticals today announced that the U.S. Patent and
Trademark Office issued patent #9,090,659, with claims covering the
composition-of-matter and use of RHAMM-binding peptides with a wide
range of potential therapeutic uses. The patent also has claims for
the diagnosis and prognosis of cancer, and for prescribing a course
of treatment for the diagnosed cancer.
Novare is developing therapeutic products that modulate the
Receptor for Hyaluronan-Mediated Motility (RHAMM), a cellular
protein that helps to regulate cell movement and stem cell
differentiation. Novare’s RHAMM-based therapeutic products aim to
safely and selectively stimulate cell differentiation as well as
reduce destructive inflammation and scarring. Potential
applications include the treatment of osteoarthritis, lung
fibrosis, and several types of cancers such as lung, breast,
prostate, and brain, as well as the prevention or reduction of
tissue scarring.
The patent was issued to Lawson Health Research Institute, and
names Drs. Leonard G. Luyt, Eva A. Turley and Mr. Kenneth V.
Esguerra as the inventors. Novare, which has an exclusive,
worldwide license to the patented technology, operates a research
incubator within the London Regional Cancer Program under the
direction of Drs. Turley and Luyt. Lawson is the research
institution of London Health Sciences Centre and St. Joseph’s
Health Care London located in Ontario, Canada.
”We are pleased to have reached this significant milestone as it
allows us to move forward with pharmaceutical compositions for the
treatment of several major diseases, including cancer,” said Dr.
Turley, who also serves as Chief Scientist for Novare.
The patent also includes imaging methods to detect pathogenic
cells, methods that can be applied to prognosis, and covers the
prescription of a course of treatment based on an individual
patient’s diagnosis and prognosis.
“The issuance of this patent is a major step forward for our
research,” said Mike Delmage, Chief Executive Officer of Novare.
“This new patent supports the therapeutic use of our RHAMM-binding
peptides in progressive disease. It also provides Novare with a
complete package for diagnosis, prognosis, and therapeutic
treatment, all based on RHAMM binding. The work we are doing around
positioning the RHAMM-binding peptides that can control
inflammatory disease and cancerous tumors is a key differentiator
for us.”
For more information about Novare’s research, see
www.novarepharma.com. The company is a subsidiary of Boston-based
Allied Minds (LSE: ALM).
About Novare Pharmaceuticals
Novare Pharmaceuticals develops therapeutic products that help
the body replenish and rebuild itself using its own tissue. By
modulating RHAMM, a natural protein that alters migratory cell
behavior, Novare is at the forefront of finding treatments for a
wide variety of inflammatory conditions, from arthritis to fibrotic
diseases including Bronchopulmonary Dysplasia (BPD) in premature
infants and Idiopathic Pulmonary Fibrosis (IPF). RHAMM modulation
also provides a means of tissue engineering that may allow the
regeneration and reconstruction of women’s breasts after a
mastectomy, and may also offer opportunities in the aesthetics
market. More information about the company can be found on its
website, www.novarepharma.com
About Lawson Health Research Institute
As the research institute of London Health Sciences Centre and
St. Joseph's Health Care London, and working in partnership with
Western University, Lawson Health Research Institute is committed
to furthering scientific knowledge to advance health care around
the world. Patenting and commercialization for Lawson is handled
through WORLDiscoveries® (www.worldiscoveries.ca), a joint venture
between Lawson and Western. As the business development arm of
London, Ontario’s extensive research network, WORLDiscoveries® is a
bridge between local invention and global industry.
www.lawsonresearch.com
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and
technology development and commercialization company. Operating
since 2006, Allied Minds forms, funds, manages and builds products
and businesses based on innovative technologies developed at
leading U.S. universities and federal research institutions. Allied
Minds serves as a diversified holding company that supports its
businesses and product development with capital, central management
and shared services. More information about the Boston-based
company can be found at www.alliedminds.com
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company’s regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Prospectus Rules, the
Listing Rules and the Disclosure and Transparency Rules, neither
the company nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150729006862/en/
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660,
x101
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024